ArticleJournal of human hypertension2026
Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG).
Article in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension and diabetes commonly coexist, sharing mechanisms such as insulin resistance, obesity, and endothelial dysfunction, which together amplify cardiovascular, renal, and cerebrovascular risk. This dual burden is particularly pronounced in the Asia-Pacific region, where rapid demographic and lifestyle transitions have led to a surge in non-communicable diseases. The Asian-Pacific Society of Hypertension (APSH) and the Diabetes Asia Study Group (DASG) have jointly developed this consensus to provide region-specific, evidence-based recommendations for managing hypertension in individuals with diabetes. A multidisciplinary panel from 15 countries formulated these recommendations using a modified Delphi approach, incorporating evidence from randomized controlled trials, meta-analyses, and international and regional guidelines published between 2015 and 2025, graded according to the GRADE framework. The consensus underscores lifestyle modification as the cornerstone of therapy, emphasizing sodium restriction, weight control, regular physical activity, and avoidance of tobacco and alcohol. Pharmacologic management should be individualized, prioritizing renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, and thiazide-like diuretics as first-line options, with single-pill combinations preferred for adherence. Emerging therapies such as sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, angiotensin receptor-neprilysin inhibitors, and mineralocorticoid receptor antagonists offer added cardio-renal protection and are recommended where appropriate. A target blood pressure of <130/80 mmHg is advised for most, with ≤140/90 mmHg for older or frail individuals. Home blood pressure monitoring is preferred for ongoing management. This consensus offers a practical, patient-centered framework to optimize cardiovascular and renal outcomes in people with diabetes and hypertension across the Asia-Pacific region.
Indexed as
Identifiers
42056284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.